PHARMACOLOGICAL PROPHYLAXIS AGAINST POSTOPERATIVE GRAFT OCCLUSION AFTER PERIPHERAL VASCULAR-SURGERY - A WORLDWIDE SURVEY

被引：17

作者：

LINDBLAD, B

WAKEFIELD, TW

STANLEY, TJ

BERGQVIST, D

NICHOL, BJ

GREENFIELD, LJ

STANLEY, JC

BERGENTZ, SE

机构：

[1] Department of Surgery, Lund University, Malmö General Hospital, Malmö

[2] Section of Vascular Surgery, Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI

[3] Department of Surgery, University Hospital, Uppsala

来源：

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY | 1995年 / 9卷 / 03期

关键词：

PHARMACOLOGICAL PROPHYLAXIS; VASCULAR RECONSTRUCTIONS; ASA; ANTICOAGULATION;

D O I：

10.1016/S1078-5884(05)80129-7

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Objectives: To define current practice regarding the use of pharmacological prophylaxis to prevent postoperative graft occlusion. Design: Prospective open questionnaire. Materials and Methods: Questionnaires regarding this subject were sent to vascular surgeons throughout the world to analyse current practice. Results: 651 questionnaires were returned with a response rate of 62% and form the basis for this report. Data from 100334 vascular reconstructions were reported in this survey. Prophylaxis against postoperative graft occlusions was common. Treatment periods were usually greater than 1 year. Among carotid surgery patients, 82% received prophylaxis, consisting mainly of low-dose acetysalicylic acid (ASA). In Mid-Europe the use of oral anticoagulation was more common than in other regions (p < 0.001). Among aneurysm surgery patients, 38% received prophylaxis. For infrainguinal bypass, ASA in low dose was the most commonly used agent worldwide. However, oral anticoagulation was mole frequent in Mid-Europe, in contrast to South America where the combination of ASA and dipyridamole was most common. Considerable geographical differences regarding patient selection, the frequency of specific procedures and operative techniques existed. Conclusions: Important world-wide differences exist regarding prophylaxis for postoperative graft occlusion.

引用

页码：267 / 271

页数：5

共 13 条

[1] Reilly, Fitzgerald, Aspirin in cardiovascular disease, Drugs, 35, pp. 154-200, (1988)
[2] Sarin, Shami, Cheatle, Bearn, Scurr, Coleridge Smith, When do vascular surgeons prescribe antiplatelet therapy? Current attitudes, Eur J Vasc Surg, 7, pp. 6-13, (1993)
[3] Van Urk, Kretschmer, What is the role of oral anticoagulants and platelet inhibitors in peripheral vascular surgery?, Eur J Vasc Surg, 4, pp. 553-555, (1990)
[4] Bergqvist, Lindblad, Pharmacological intervention to increase patency after arterial reconstructions, (1989)
[5] Antiplatelet Trialists' Collaboration, Secondary prevention of vascular disease by prolonge antiplatelet treatment, BMJ, 296, pp. 320-331, (1988)
[6] Bischof, Pratschner, Kail, Mittlbock, Turkof, Puig, Polterauer, Kretschmer, Anticoagulants antiaggregants or nothing following carotid endarterectomy?, Eur J Vasc Surg, 7, pp. 364-369, (1993)
[7] Wakefield, Lindblad, Stanley, Nichol, Greenfield, Bergentz, Heparin and protamine use in peripheral vascular surgery: A comparison between surgeons of the Society for Vascular Surgery and the European Society for Vascular Surgery, Eur J Vasc Surg, 8, pp. 193-198, (1994)
[8] Bergqvist, Ökning av artärkirurgi men stora regionala skillnader, Läkartidningen, 87, pp. 369-371, (1990)
[9] Ernst, Rutkow, Cleveland, Folse, Johnson, Stanley, Vascular surgery in the United States. Report of the joint society for vascular surgery — International society for cardiovascular surgery committee on vascular surgical manpower, J Vasc Surg, 6, pp. 611-621, (1987)
[10] Sze, Reitman, Pincus, Sacks, Chalmers, Antiplatelet agents in the secondary prevention of stroke: metaanalysis of the randomized control trials, Stroke, 19, pp. 436-442, (1988)

← 1 2 →